Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Merck Sharp & Dohme (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (138)
ARTG (79)
Prescription medicine registration (61)
Australian public assessment report (AusPar) (33)
Designation or determination (31)
Prescription medicine evaluation (4)
Prescription medicine decision summary (2)

Date

2025 (35)
2024 (23)
2023 (32)
2022 (29)
2021 (31)
2020 (37)
2019 (52)
2018 (23)
2017 (3)
2016 (10)
2015 (6)
2014 (9)
2013 (13)
2012 (6)
2011 (4)
2009 (10)
2008 (1)
2007 (2)
2006 (8)
2005 (1)
2003 (1)
2002 (3)
2000 (1)
1998 (1)
1997 (5)
1993 (1)
1991 (1)

Search

Sponsor content

348 result(s) found, displaying 201 to 210

JANUMET HCI, JANUMET XR, VELMETIA, VELMETIA XR (Merck Sharp & Dohme (Australia) Pty Ltd)

9 October 2019

Prescription medicine registration

Active ingredients: sitagliptin phosphate monohydrate; metformin hydrochloride.
JANUVIA, XELEVIA (Merck Sharp & Dohme (Australia) Pty Ltd)

9 October 2019

Prescription medicine registration

Active ingredients: sitagliptin phosphate monohydrate.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

17 September 2019

Prescription medicine registration

Active ingredients: pembrolizumab.
AVANZA mirtazapine 45mg film coated tablets blister pack Cancelled under Section 30(1)(c) of the Act

3 September 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
MIRTAZON mirtazapine 45mg film coated tablets blister pack Cancelled under Section 30(1)(c) of the Act

3 September 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
BELSOMRA suvorexant 20mg tablet blister pack (207712)

16 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for BELSOMRA suvorexant 20mg tablet blister pack.
BELSOMRA suvorexant 15mg tablet blister pack (207709)

16 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for BELSOMRA suvorexant 15mg tablet blister pack.
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

5 August 2019

Prescription medicine registration

Active ingredients: pembrolizumab.
REMERON SOLTAB mirtazapine 45mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

2 August 2019

Cancellation by sponsor

Requested by Merck Sharp & Dohme (Australia) Pty Ltd
KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)

11 July 2019

Prescription medicine registration

Active ingredients: pembrolizumab.

Pages

First page
Previous page
…
Page 17
Page 18
Page 19
Page 20
Current page 21
Page 22
Page 23
Page 24
Page 25
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.